Both observational studies and recent randomized trials indicate that Bacillus Calmette-Guérin vaccination (BCG) is associated with beneficial nonspecific effects (NSEs) ([@bib1],[@bib2],[@bib3],[@bib4],[@bib5],[@bib6]), reducing mortality from infections other than tuberculosis. The immunological mechanisms underlying NSEs are not clear ([@bib7]). Recent studies by Kleinnijenhuis *et al*. suggest that "trained immunity" mediated via functional reprogramming of the monocytes may play an important role ([@bib8]). Effects on the adaptive immune system are also a possibility ([@bib9],[@bib10]).

The thymus is essential in the generation and maturation of T cells and therefore, also in generating a normally functioning immune system ([@bib11]). The size of the thymus has been shown to be important for infant survival in low-income countries. In Guinea-Bissau thymic size at birth, measured as thymic index (TI), was found to have a stronger association with survival than body weight ([@bib12]), and among 6-mo-old children, a doubling of the thymic size was associated with a 72% reduction in mortality up to 3 y of age ([@bib13]).

Based on the facts that both BCG vaccination and a large thymus have been associated with increased infant survival, we hypothesized that the BCG-induced beneficial nonspecific effects were mediated by increasing thymic size.

Within The Danish Calmette Study, a randomized clinical trial testing the effect of receiving BCG vs. no BCG at birth on health outcomes ([@bib14]), we tested the hypothesis that BCG vaccination at birth results in increased thymic size, absolutely and relatively, by 3 mo of age. Furthermore, we evaluated the association between thymic output and thymic size, and the association between episodes of infections in the first 3 mo of life and thymic size at birth.

Methods
=======

Overall Setting and Study Design
--------------------------------

This study was nested within The Danish Calmette Study, which was conducted between October 2012 and January 2015, and has been described in detail elsewhere ([@bib14]). In brief, The Danish Calmette Study is a randomized clinical multicenter trial with 1:1 allocation of 4,262 infants to either BCG vaccination or no BCG vaccination within 7 d of birth. The inclusion criteria were gestational age ≥ 32 wk and a birth weight ≥ 1,000 g. Exclusion criteria were maternal intake of immune modulating medicine during pregnancy, severe illness, or major malformations. The intervention group was vaccinated intradermally with BCG vaccine (SSI strain 1331), in the standard dose of 0.05 ml in the upper, lateral part of the left shoulder. Background information on demographics and risk factors were collected by a structured telephone interview conducted in the third trimester of pregnancy.

Study Population
----------------

From March to November 2013, all children born at Copenhagen University Hospital, Hvidovre were invited to participate in this substudy including a thymus scan at randomization and at 3 mo follow up. By coincidence, none of the children were preterm children, hence our study population consisted of term (born between gestational weeks 37 + 0 to 41 + 6) children only. A subgroup of these infants were further included into a substudy on T and B cells (N.M. Birk *et al.* The effect of neonatal Bacillus Calmette-Guérin vaccination on T and B lymphocyte subsets: a clinical randomized trial (unpublished data) and had blood samples collected for flow cytometry analyses (**[Figure 1](#fig1){ref-type="fig"}**).

Baseline Measurements
---------------------

Immediately following randomization the children had their thymic size measured by ultrasound. This was again immediately followed by vaccination of the BCG group. The blood sample used for measuring T and B cells cell subsets by flow cytometry was collected 4 d (± 2d) after the randomization, ultrasound examination, and vaccination.

Follow-up
---------

At 3 mo of age, before having received any standard childhood vaccines, all infants were invited for a clinical examination at the hospital preceded by a follow-up telephone interview including questions about number of illness episodes in the first 3 mo of life. Questions on episodes of illness were designed to target illness due to infections ([@bib15]) and parents were encouraged to take notes of their child's illness in a diary supplied by study staff at the time of randomization. As part of the clinical examination, thymic size was assessed again. Following the clinical examination, another blood sample was obtained (**[Figure 1](#fig1){ref-type="fig"}**).

Ultrasound Examination of the Thymus
------------------------------------

By transsternal ultrasound, thymic size was estimated as thymic index (TI) and thymic weight index (TWI), an absolute and relative volume estimate, respectively. First, the thymus gland was identified in a horizontal scanning plane and the largest transverse diameter of the thymus was obtained (**[Figure 2a](#fig2){ref-type="fig"}**). Second, in a sagittal scanning plane, the area of the largest lobe was assessed (**[Figure 2b](#fig2){ref-type="fig"}**). Both measurements were obtained twice, and in case of more than 15% difference, both measurements were repeated. The means of each of the two measurements were multiplied and the value was defined as the thymic index (cm^3^) ([@bib16]). For the weight-adjusted index TWI, TI was divided by weight of the child in kilograms (cm^3^/kg). All measurements were conducted with a Sonosite MicroMaxx transportable ultrasound scanner with an 8--5 MHz C11e transducer, manufactured by SonoSite, Bothell, WA.

As thymus scans were performed by two investigators and interobserver variation has been reported ([@bib12]), the potential interobserver variation in this study was assessed; we found no significant difference between observers (**Supplementary Methods S1** online).

T Cell Subsets, Flow Cytometry, and Lymphocytes
-----------------------------------------------

For the measurement of lymphocytes, blood was collected in K2EDTA (ethylenediaminetetraacetic acid) tubes (Greiner Bio-One, Kremsmünster, Austria). Differential white blood cell count was measured by standard technique using a Sysmex XE-5000 at the Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, Denmark.

CD4^+^ T cells, CD8^+^ T cells, CD4^+^ RTEs (CD4^+^CD45RA^+^CD31^+^), and CD8^+^ RTEs (CD8^+^CD45RA^+^CD31^+^) were measured in peripheral blood using a 6-color FACS Canto (Becton Dickinson (BD), Franklin Lakes, NJ) and data were processed using FACS Diva software (BD). In brief, 100 µl of EDTA blood was incubated with fluorescent dye-conjugated monoclonal antibodies at room temperature for 20 min according to the manufacturer's instructions. Erythrocytes were then lysed with 2 ml of Lysing Solution (BD) at room temperature for 20 min, and samples were washed and resuspended in FACS Flow (BD). Monoclonal antibodies used were isotype control IgG1 peridinin chlorophyll proteins--cyanine (PerCP-Cy5.5), IgG1 fluorescein isothiocyanate (FITC),IgG2b allophycocyanin (APC), and IgG1 allophycocyanin combined with an analog of Cy7 (APC-H7) further CD8-PerCPCy5.5, CD31-FITCH, CD45RA-APC, and CD4-APC-H7 all purchased from BD.

Power Calculation
-----------------

A *post hoc* power calculation was conducted based on previous work with thymic index, where mean TI in infants at 4 mo of age was 3.0 cm^3^ (SD 1.5). To detect a difference of 20% in the intervention group, we needed to include 132 in each group; thus the number of included infants (156 in the intervention group and 158 in the control group) provided suitable power (α: 0.05, β 0.9, two-sided test).

Statistical Methods
-------------------

To obtain normal distribution, TI and TWI were log-transformed. The primary estimate of the BCG-effect on TI was the geometric mean ratio (GMR) with 95% confidence interval (CI) obtained as the anti-logged coefficient from a linear regression with log-TI as outcome and randomization group and baseline log-TI as covariates. The primary estimate of the BCG-effect on TWI was obtained similarly. The interpretation of a TI GMR of eg.1.15 being that children randomized to BCG vaccination had a 15% larger TI than their controls.

We had few missing values of both outcome variables and covariates, and complete case analyses were done; i.e., we included only children for whom all information was available.

On the basis of previous findings of BCG having more pronounced beneficial nonspecific effects in girls ([@bib17]), both overall and sex-stratified primary outcome estimates were calculated. Furthermore, we had prespecified that we would investigate potential effect modification by gestational age, birth weight, cesarean section, antibiotics given to the mother during labor, maternal BCG, ethnicity of the parents, atopic predisposition, siblings, and age at randomization (day 0--1 vs. 2--7).

The analysis of the association between T cells, lymphocytes, and TI/TWI was done using linear regression analysis with absolute cell count and lymphocytes as outcomes, and log2-TI/log2-TWI as covariates. Cell measurements were done 4 d postrandomization, so we adjusted for BCG/no BCG.

The analysis of the association between episodes of illness and TI/TWI was assessed in Poisson regression test for trend using a categorical variable of none or at least one episode of parent-reported illness during the first 3 mo as outcome and TI/TWI as quartiles and sex as covariates. These analyses were adjusted for BCG/no BCG.

All analyses were performed using STATA 13.1 (StataCorp LP, College Station, TX).

Ethical Considerations
----------------------

This study was approved by the Committees on Biomedical Research Ethics (J.no. H-3-2010-087), the Danish Data Protection Board (J.no. 2009-41-4141), and the Danish Medicines Agency (J.no. 2612--4356.EudraCT 2010-021979-85. Protocol 2009--323).

The study was registered at <http://www.clinicaltrials.gov> with registration number NCT01694108. The trial was supervised by the Good Clinical Practice Units of the Capital Region, Denmark and monitored by an independent Data Safety Monitoring board.

The ultrasound examination did not cause any discomfort in the infants and is not known to be associated with any adverse events ([@bib18]). Infants were included after both oral and written information was provided and a signed consent form from both parents was obtained. The study was conducted according to The Declaration of Helsinki.

Results
=======

A total of 314 healthy term infants were included in the study and had an ultrasound examination of the thymus at birth, 156 were randomized to BCG and 158 to no BCG.

The two groups had similar baseline characteristics although infants in the BCG group were on average 0.11 kg heavier at birth (*P* = 0.04) (**[Table 1](#tbl1){ref-type="table"}**). At baseline, the two groups had similar thymic size, the GMR in the BCG vs. the control group being 1.02 (0.95--1.09) for TI and 0.99 (0.93--1.05) for TWI (**[Table 2](#tbl2){ref-type="table"}**).

Parents of 1% of the infants (3/314) withdrew consent to participate and 3% (10/314) were lost to follow-up. There was no significant difference in the proportion of dropouts between groups (BCG 2% (*n* = 3) vs. no BCG 6% (*n* = 10), *P* = 0.09) (**[Table 1](#tbl1){ref-type="table"}**).

The remaining 301 infants were scanned at 3 mo follow-up (mean age = 90 d). There were no significant differences between groups with regard to age, weight, breastfeeding, parent-reported illness at follow-up, or general practitioner consultations (GP) (**[Table 1](#tbl1){ref-type="table"}**).

The GM of TI was 12.8 vs. 12.6 (cm^3^) in the BCG group vs. the control group at birth, and 33.0 vs. 34.2 (cm^3^) at follow-up. For TWI, it was 3.6 vs. 3.7 (cm^3^/kg) at birth, and 5.4 cm^3^ vs. 5.6 (cm^3^/kg) at follow-up, respectively (**[Table 2](#tbl2){ref-type="table"}**). Useful measurements were obtained for all children at baseline and at follow-up.

Effect of BCG on TI/TWI
-----------------------

No difference in thymic size at follow-up was found when comparing the BCG and the control group with regard to TI, the GMR being 0.96 (0.89--1.02), and TWI (GMR: 0.96 (0.90--1.02)) (**[Table 2](#tbl2){ref-type="table"}**). Adjusting for weight at baseline did not change the estimates (data not shown).

Potential Effect Modification
-----------------------------

No effect modification by sex on the effect of BCG on TI at follow-up was found. The GMR was 0.92 (0.84--1.01) in males and 0.98 (0.90--1.09) in females, *P* = 0.30 for interaction (**[Table 2](#tbl2){ref-type="table"}**). The same was seen for TWI (**[Table 2](#tbl2){ref-type="table"}**).

For children with no siblings, BCG was associated with a smaller TI (GMR: 0.92 (0.84--0.99)), *P* value for interaction = 0.07, and a smaller TWI (GMR: 0.91 (0.85--0.99)) at 3 mo of age, *P* value for interaction = 0.05 (**[Table 3](#tbl3){ref-type="table"}**). None of the other pre-specified effect modifiers influenced the effect of BCG (**[Table 3](#tbl3){ref-type="table"}**).

Association Between T Lymphocyte Cell Subsets, Lymphocytes, and TI/TWI
----------------------------------------------------------------------

At birth, we found a positive association between CD4^+^ T cells, CD8^+^ T cells, CD4^+^ recent thymic emigrants (RTEs), CD8^+^ RTEs, lymphocytes (*n* = 112), and TI (**[Figure 3](#fig3){ref-type="fig"}**). The positive association was stronger when looking at CD4^+^ T cells and TWI (Regression coefficient (a): 973 cells/µl per doubling of TWI, 95% CI 561--1,386, *P* \< 0.001), CD8^+^ T cells (a: 146 cells/µl pr. doubling of TWI, 95% CI 4--287, *P* = 0.044), CD4^+^ RTEs (a: 595 cells/µl pr. doubling of TWI, 95% CI 323--867, *P* \< 0.001), CD8^+^ RTEs (a: 154 cells/µl pr. doubling of TWI, 95% CI 16--292, *P* = 0 .028), and lymphocytes (a: 1,498 cells/µl pr. doubling of TWI, 95% CI 924--2,072, *P* \< 0.001). The interpretation being that a doubling of TWI increases circulating lymphocytes by 1,498 cells/µl. At 3 mo of age, there were no associations between cell subsets (*n* = 106) and TI/TWI (data not shown).

Association Between Episodes of Infectious Diseases and TI/TWI
--------------------------------------------------------------

When looking at the association between infections assessed as none or at least one episode of infections during the first 3 mo of life and thymic size at birth in quartiles, a test for trend showed that with each step up in quartile, the incidence of infections decreased by 25% (RR: 0.75, 95% CI 0.55--1.05, *P* = 0.09 for TI); and 27% (RR: 0.73, 95 % CI 0.54--0.99, *P* = 0.04) for TWI. Compared with children in the three lower quartiles of TI, the children in the highest quartile had a 58% (IRR 0.42, 95% CI 0.13--1.35, *P* = 0.20) decrease in risk of infections; for TWI it was 75% (IRR 0.25, 95% CI 0.06--1.03, *P* = 0.05) (**[Figure 4](#fig4){ref-type="fig"}**). We found no association between number of general practitioner consultations and TI/TWI (data not shown).

Discussion
==========

BCG vaccination at birth did not affect thymic size, assessed by ultrasound as TI and TWI at birth and in 3-mo-old infants. Thymic size at birth was associated with increasing numbers of circulating lymphocytes and T cell subsets recently generated in the thymus as well as with reduced risk of parent-reported infections.

Strengths of this study were the randomized design, the low drop-out rate (4%), and that examiners were blinded. This study was not designed to assess the associations between T cells, infections, and TI/TWI. However, the analyses represent an internal quality control in this study and the associations are in line with previous findings. The overall number of infections in the first 3 mo of life is low and numbers were parent reported, representing a potential weakness in the assessment of the association between infections and thymic size.

To our knowledge, this is the first randomized trial testing the effect of BCG on thymic size in newborns in a high income country. In West Africa Eriksen *et al*. tested the effect of providing BCG at birth to low-birth-weight infants compared to the usual practice of postponing BCG until infants had reached a weight of 2.5 kg (Eriksen *et al*., "The effect of early Bacille Calmette-Guérin vaccine on thymic size in low birth weight infants in Guinea-Bissau", personal communication.). Consistent with the present study, no overall or sex differential effect on TI or TWI after 4 wk was found. Caution in comparing the two cohorts should be taken as inclusion criteria differed and the settings were different in many aspects ([@bib19]).

We observed a tendency for BCG being associated with diminished thymic growth among children with no siblings, but not among children with siblings (**[Table 3](#tbl3){ref-type="table"}**). This may be caused by baseline differences; the BCG group had a smaller geometric mean in the "no siblings" group compared to the "siblings" group at baseline which seemed to be sustained at 3 mo.

Thus, based on the existing studies, BCG does not exert nonspecific effects by modifying thymic size. With the introduction of the concept "Trained immunity" Kleinnijenhuis *et al.* challenge the paradigm that immunological memory after BCG is restricted to the adaptive immune response by showing that BCG induced an enhanced release of monocyte-derived cytokines to unrelated pathogens, mediated by epigenetic reprogramming of innate immune cells independently of B and T cells ([@bib8]). If the explanation for the observed beneficial NSEs of BCG is due to modulations of the innate immune response this could explain our finding of no effect on thymic size.

We found significant positive associations between the absolute count of CD4^+^ RTEs, CD8^+^ RTEs CD4^+^ T cells, CD8^+^ T cells, lymphocytes, and thymic size in the newborn. This was strongest for lymphocytes, and stronger for the weight-adjusted TWI compared to TI, indicating that a doubling in TWI increases the amount of circulating lymphocytes by 1,498 cells/µl. This links neonatal thymic size to immune function. To our knowledge this is the first time an association between specific thymic output measured as RTEs and TI/TW has been shown. An association between proportions of CD8+ T cells but not CD4+ T cells and TI at 10 mo of age has earlier been shown ([@bib20]), others found no correlation between proportions of CD4+ and CD8+ T cells and TI ([@bib21],[@bib22]). RTEs constitute an early population of T cells recently generated in the thymus and exported into the peripheral blood. Recently, it was reported that measuring CD4+ RTEs by flow cytometry, using CD31 as a surface biomarker as in our study, is as valid as measuring T cell receptor excision circles (TRECs) with regard to evaluating thymic output ([@bib23]). Our findings suggest that the used ultrasonic assessment of TI/TWI may be useful in evaluating neonatal thymic output. A method which is noninvasive, considered safe ([@bib18]), shown to be reproducible and correlate with autopsy findings of actual thymic volume ([@bib16]). However, we are not able to conclude on the causality between thymic size, lymphocytes and risk of infection; hence it is possible that thymic size, T cells subsets and peripheral lymphocytes are all "barometers of good health," but do not play a causal role in infants having fewer infections.

None of the infants in the present study were premature, low for gestational age, lymphopenic, or showed signs or symptoms of immunodeficiency. If the association between function and size of the thymus is similar in immunologically challenged infants, a small thymus at birth may result in a low peripheral T cell pool and a narrow T cell repertoire. This could provide a potential biological mechanism behind the findings of mortality being inversely related to thymic size ([@bib12],[@bib24]). Several factors are known to affect thymic size, both in a thymopoietic (e.g., weight, gestational age, breastfeeding) and a thymolytic (e.g., infection, physiological stress, glucocorticoids and age) manner ([@bib25]). The influence by several different factors on thymic size might explain why the association between output and size becomes nonsignificant at age 3 mo.

Our results of reduced risk of infections in the first 3 mo of life with increasing thymic size at birth support findings of an association between infectious disease and thymic size. Previous studies have mainly shown that infections in a high income country lead to a smaller thymic size ([@bib26]), but in this study we show that a larger thymic size at birth leads to fewer infections. This finding corroborates findings from West Africa, where a large thymic size was associated with reduced mortality ([@bib12],[@bib13]). To our knowledge, this is the first time thymic size has been shown to potentially predict subsequent health measured as reduced number of infections in a high income country.

In conclusion, BCG vaccination at birth does not affect thymic size at 3 mo of age measured as thymic index and thymic/weight index in healthy term infants. Overall, the study supported that thymic size may be a marker of subsequent health due to less infectious disease, and demonstrated, for the first time, a positive association between thymic size and RTEs. Ultrasound to assess TI and TWI may be a useful way to identify immunologically vulnerable neonates in low income settings where flow cytometry is not an option.
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![Flowchart of infants randomized to BCG or no BCG at birth in the study on BCG and thymic size and the association between T cells, infections, and thymic size.](pr201727f1){#fig1}

![Sonograms. Ultrasonic assessment of thymic size. An immunological evaluation within The Danish Calmette Study randomizing infants to BCG or no BCG at birth. (**a**) In a horizontal scanning plane the thymus is seen as an echo-poor structure surrounded by its echo-rich capsule surrounding the big vessels (Pulmonary artery and Ascending aorta).The largest transverse diameter of the thymus is measured (dashed line). (**b**) In a sagittal scanning plane, the area of the largest lobe is assessed (dashed line).](pr201727f2){#fig2}

![Plots of the association between T cell subsets, lymphocytes, and thymic index in newborns randomized to BCG or no BCG. (**a**) The association between the absolute cell count (cells/μl) of recent thymic emigrants (RTEs) and TI at 4 d. The linear regression coefficient for CD4+ RTEs (filled circles) = 523 cells/μl pr. doubling of TI, 95 % CI 281--764, *P* \< 0.001 and for CD8+ RTEs (open circles) = 169, 95% CI 48--290, *P* = 0.007, *n* = 112. (**b**) The association between the absolute cell count (cells/μl) of CD4+ and CD8+ T cells and TI at 4 d. The linear regression coefficient for CD4+ (filled circles) = 849 cells/μl pr. doubling of TI, 95% CI 483--1,215, *P* \< 0.001 and for CD8+ (open circles) = 165, 95% CI 41--290, *P* = 0.01, *n* = 112. (**c**) The association between the absolute cell count (cells/μl) of lymphocytes and TI at 4 d. The linear regression coefficient = 1,340 cells/μl pr. doubling of TI, 95% CI 831--1,849, *P* \< 0.001, *n* = 112.](pr201727f3){#fig3}

![The association between thymic weight index at birth and subsequent infections in term infants. Infants are grouped into categories with none or at least 1 episodes of parent reported infections in the first 3 mo of life. Thymic size is given as quartiles of thymic weight index at birth. Compared with children in the three lower quartiles of TI, the children in the highest quartile had a 75% decrease in risk of infections, *P* = 0.05.](pr201727f4){#fig4}

###### Background characteristics at baseline and at follow-up 3 mo later in infants randomized to BCG or no BCG at birth
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###### Overall and sex-specific effects of BCG vs. no BCG on thymic index (TI) and thymic weight index (TWI)
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###### The effect of BCG at birth on thymic index/thymic weight index measured at 3 mo of age, stratified by baseline covariates
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